{"entity":{"id":"nct07195591","kind":"trial","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","aka":[],"tldr":"A phase 3 trial of Temozolomide in glioma & glioblastoma, run by GT Medical Technologies, Inc., now recruiting.","summary":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care is a phase 3 interventional study registered as NCT07195591 by GT Medical Technologies, Inc., with 766 participants planned, started 2025-12-10 and due to reach its primary completion in 2031-12. Interventions recorded: GammaTile®, External Beam Radiation Therapy and Temozolomide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07195591","url":"https://clinicaltrials.gov/study/NCT07195591"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":["gt-medical-technologies"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07195591","phase":"3","setting":"Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)","sponsor":"GT Medical Technologies, Inc.","enrolled":766,"outcomes":[]},"route":"/trials/nct07195591/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/"}]}}